Lipocine (NASDAQ: LPCN) presents LPCN 2101 epilepsy posters at AES 2025
Rhea-AI Filing Summary
Lipocine Inc. reported that it presented scientific posters on its epilepsy drug candidate LPCN 2101 at the American Epilepsy Society Annual Meeting in Atlanta. The company highlighted clinical pharmacokinetics and tolerability data for this novel oral GABA A receptor positive allosteric modulating candidate for epilepsy, along with oral toxicokinetics data for a bioidentical GABA A receptor modulating neuroactive steroid anti-seizure medication candidate for women with epilepsy.
The posters are furnished as Exhibits 99.1 and 99.2 to the report, giving readers more detail on how LPCN 2101 behaves in the body and how well it was tolerated in the studies described.
Positive
- None.
Negative
- None.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact name of registrant as specified in its charter)
Commission
File No.
(State or other jurisdiction of incorporation) |
(IRS Employer Identification Number) |
(Address of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code:
Former name or former address, if changed since last report: Not Applicable
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4© under the Exchange Act (17 CFR 240.13©(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01 | Other Events. |
The Company presented posters for LPCN 2101 at the American Epilepsy Society (AES) Annual Meeting held December 5th through the 9th, 2025 in Atlanta, GA. The posters are furnished as Exhibit 99.1 and 99.2 to this report and incorporated by reference herein.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
The following exhibits are filed with this report:
| Exhibit No. | Description | |
| 99.1 | Poster entitled “Clinical Pharmacokinetics and Tolerability of a Novel Oral GABAA Receptor Positive Allosteric Modulating Candidate for Epilepsy” | |
| 99.2 | Poster entitled “Oral Toxicokinetics of a Bioidentical GABAA Receptor Modulating Neuroactive Steroid Anti-Seizure Medication Candidate for Women with Epilepsy” | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| LIPOCINE INC. | ||||
| Date: | December 11, 2025 | By: | /s/ Mahesh V. Patel | |
| Mahesh V. Patel | ||||
| President and Chief Executive Officer | ||||
FAQ
What did Lipocine Inc. (LPCN) disclose in this report?
Lipocine Inc. disclosed that it presented scientific posters for its epilepsy drug candidate LPCN 2101 at the American Epilepsy Society Annual Meeting in Atlanta, Georgia.
What is LPCN 2101 in the Lipocine (LPCN) filing?
In this report, LPCN 2101 is described through posters as a novel oral GABA A receptor positive allosteric modulating candidate for epilepsy and as a bioidentical GABA A receptor modulating neuroactive steroid anti-seizure medication candidate for women with epilepsy.
Where and when were Lipocine’s LPCN 2101 posters presented?
The posters for LPCN 2101 were presented at the American Epilepsy Society (AES) Annual Meeting, held December 5–9, 2025 in Atlanta, Georgia.
What does Exhibit 99.1 contain in the Lipocine (LPCN) report?
Exhibit 99.1 is a poster entitled “Clinical Pharmacokinetics and Tolerability of a Novel Oral GABA A Receptor Positive Allosteric Modulating Candidate for Epilepsy,” summarizing pharmacokinetic and tolerability findings for LPCN 2101.
What does Exhibit 99.2 contain in the Lipocine (LPCN) report?
Exhibit 99.2 is a poster entitled “Oral Toxicokinetics of a Bioidentical GABA A Receptor Modulating Neuroactive Steroid Anti-Seizure Medication Candidate for Women with Epilepsy,” focusing on toxicokinetics data for LPCN 2101.
What type of information does this Lipocine (LPCN) report emphasize?
The report emphasizes scientific and clinical information about LPCN 2101, including clinical pharmacokinetics, tolerability, and oral toxicokinetics, presented through posters at a major epilepsy conference.
